Your browser doesn't support javascript.
Development of the India COVID-19 vaccine tracker.
Singh, Harpreet; Lohia, Rohan; George, Leyanna Susan; Gupta, Nivedita; Thangaraj, Jeromie Winsley; Rana, Salaj; Rana, Shweta; Kaur, Jasmine; Shivam, Shashwat; Arora, Narendra Kumar; Muliyil, Jai Prakash; Murhekar, Manoj V; Lodha, Rakesh; Pandey, R M; Rao, Vishnu Vardhan; Dhandore, Suhas; Malik, Akash; Kumar, Vijay; Tripathi, Ankit; Panda, Samiran; Bhargava, Balram.
  • Singh H; Division of Bio-Medical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Lohia R; Clinton Health Access Initiative, India Office, All India Institute of Medical Sciences, New Delhi, India.
  • George LS; Clinical Studies, Trials & Projections Unit, Indian Council of Medical Research, New Delhi, India.
  • Gupta N; Virology Unit, Indian Council of Medical Research, New Delhi, India.
  • Thangaraj JW; ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Rana S; Division of Bio-Medical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Rana S; Division of Bio-Medical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Kaur J; Division of Bio-Medical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Shivam S; Clinton Health Access Initiative, India Office, All India Institute of Medical Sciences, New Delhi, India.
  • Arora NK; The INCLEN Trust International, Delhi, India.
  • Muliyil JP; Department of Community Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
  • Murhekar MV; ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
  • Lodha R; Department of Paediatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Pandey RM; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
  • Rao VV; ICMR-National Institute of Medical Statistics, New Delhi, India.
  • Dhandore S; Division of Immunization, Ministry of Health & Family Welfare, New Delhi, India.
  • Malik A; United Nations Development Programme, New Delhi, India.
  • Kumar V; Division of eHealth, Ministry of Health & Family Welfare, New Delhi, India.
  • Tripathi A; Division of Centre for Health Informatics, Ministry of Health & Family Welfare, New Delhi, India.
  • Panda S; Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
  • Bhargava B; Indian Council of Medical Research, New Delhi, India.
Indian J Med Res ; 155(5&6): 513-517, 2022.
Article in English | MEDLINE | ID: covidwho-2281625
ABSTRACT
COVID-19 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Since then, efforts were initiated to develop safe and effective vaccines. Till date, 11 vaccines have been included in the WHO's emergency use list. The emergence and spread of variant strains of SARS-CoV-2 has altered the disease transmission dynamics, thus creating a need for continuously monitoring the real-world effectiveness of various vaccines and assessing their overall impact on disease control. To achieve this goal, the Indian Council of Medical Research (ICMR) along with the Ministry of Health and Family Welfare, Government of India, took the lead to develop the India COVID-19 Vaccination Tracker by synergizing three different public health databases National COVID-19 testing database, CoWIN vaccination database and the COVID-19 India portal. A Vaccine Data Analytics Committee (VDAC) was constituted to advise on various modalities of the proposed tracker. The VDAC reviewed the data related to COVID-19 testing, vaccination and patient outcomes available in the three databases and selected relevant data points for inclusion in the tracker, following which databases were integrated, using common identifiers, wherever feasible. Multiple data filters were applied to retrieve information of all individuals ≥18 yr who died after the acquisition of COVID-19 infection with or without vaccination, irrespective of the time between vaccination and test positivity. Vaccine effectiveness (VE) against the reduction of mortality and hospitalizations was initially assessed. As compared to the hospitalization data, mortality reporting was found to be much better in terms of correctness and completeness. Therefore, hospitalization data were not considered for analysis and presentation in the vaccine tracker. The vaccine tracker thus depicts VE against mortality, calculated by a cohort approach using person-time analysis. Incidence of COVID-19 deaths among one- and two-dose vaccine recipients was compared with that among unvaccinated groups, to estimate the rate ratios (RRs). VE was estimated as 96.6 and 97.5 per cent, with one and two doses of the vaccines, respectively, during the period of reporting. The India COVID-19 Vaccination Tracker was officially launched on September 9, 2021. The high VE against mortality, as demonstrated by the tracker, has helped aid in allaying vaccine hesitancy, augmenting and maintaining the momentum of India's COVID-19 vaccination drive.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Indian J Med Res Year: 2022 Document Type: Article Affiliation country: Ijmr.ijmr_3500_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Indian J Med Res Year: 2022 Document Type: Article Affiliation country: Ijmr.ijmr_3500_21